Innovative vaccine approaches-a Keystone Symposia report

Jennifer Cable¹, Rino Rappuoli², Elizabeth J Klemm³, Gagandeep Kang⁴, Ankur Mutreja⁵, Gavin J Wright^{6

7}, Mariagrazia Pizza², Sowmya Ajay Castro⁸, Joseph P Hoffmann⁹, Galit Alter^{10

11}, Andrea Carfi¹², Andrew J Pollard¹³, Florian Krammer¹⁴, Ravindra K Gupta^{5

15}, Caroline E Wagner¹⁶, Viviane Machado¹⁷, Kayvon Modjarrad¹⁸, Lawrence Corey^{19

20

21}, Peter B Gilbert²¹, Gordon Dougan⁵, Nicole Lurie^{22

23}, Pamela J Bjorkman²⁴, Christopher Chiu²⁵, Elisa Nemes²⁶, Stephen B Gordon²⁷, Andrew C Steer^{28

29

30}, Thomas Rudel³¹, Catherine A Blish^{32

33}, John Tyler Sandberg³⁴, Kiva Brennan³⁵, Keith P Klugman³⁶, Lynda M Stuart^{37

38}, Shabir A Madhi³⁹, Christopher L Karp³⁸

Affiliations

¹ PhD Science Writer, New York, New York.
² GSK, Siena, Italy.
³ Wellcome Trust, Bloomsbury, London, UK.
⁴ Division of Gastrointestinal Sciences, Christian Medical College, Vellore, India.
⁵ Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID) and Department of Medicine, University of Cambridge, Cambridge, UK.
⁶ Cell Surface Signalling Laboratory, Wellcome Sanger Institute, Hinxton, UK.
⁷ Department of Biology, Hull York Medical School, and York Biomedical Research Institute, University of York, York, UK.
⁸ Division of Molecular Microbiology, School of Life Sciences, University of Dundee, Dundee, UK.
⁹ Departments of Pediatrics and Medicine, Center for Translational Research in Infection and Inflammation, Tulane University School of Medicine, New Orleans, Louisiana.
¹⁰ Ragon Institute of MGH, MIT and Harvard, Harvard Medical School, Cambridge, Massachusetts.
¹¹ Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
¹² Moderna Inc., Cambridge, Massachusetts.
¹³ Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford, UK.
¹⁴ The Tisch Cancer Institute and Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York.
¹⁵ Africa Health Research Institute, Durban, South Africa.
¹⁶ Department of Bioengineering, McGill University, Montreal, Quebec, Canada.
¹⁷ Measles and Respiratory Viruses Laboratory, WHO/NIC, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, Brazil.
¹⁸ Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland.
¹⁹ Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, Washington.
²⁰ Department of Medicine, University of Washington School of Medicine, Seattle, Washington.
²¹ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
²² Coalition for Epidemic Preparedness Innovations, Oslo, Norway.
²³ Harvard Medical School, Boston, Massachusetts.
²⁴ Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, California.
²⁵ Department of Infectious Disease, Imperial College London, London, UK.
²⁶ Division of Immunology, Department of Pathology, South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
²⁷ Malawi Liverpool Wellcome Research Programme, Blantyre, Malawi.
²⁸ Infection and Immunity, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
²⁹ Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia.
³⁰ Department of General Medicine, The Royal Children's Hospital, Melbourne, Victoria, Australia.
³¹ Microbiology Biocenter, University of Würzburg, Würzburg, Germany.
³² Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford Immunology Program, Stanford University School of Medicine, Stanford, California.
³³ Chan Zuckerberg Biohub, San Francisco, California.
³⁴ Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.
³⁵ National Children's Research Centre, Crumlin and School of Medicine, Trinity College Dublin, Dublin, Ireland.
³⁶ Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia.
³⁷ Immunology Program, Benaroya Research Institute at Virginia Mason, Seattle, Washington.
³⁸ Bill & Melinda Gates Foundation, Seattle, Washington.
³⁹ South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand, Johannesburg, South Africa.

PMID: 35029310
DOI: 10.1111/nyas.14739

Innovative vaccine approaches-a Keystone Symposia report

Jennifer Cable et al. Ann N Y Acad Sci. 2022 May.

. 2022 May;1511(1):59-86.

doi: 10.1111/nyas.14739. Epub 2022 Jan 14.

Authors

Affiliations

¹ PhD Science Writer, New York, New York.
² GSK, Siena, Italy.
³ Wellcome Trust, Bloomsbury, London, UK.
⁴ Division of Gastrointestinal Sciences, Christian Medical College, Vellore, India.
⁵ Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID) and Department of Medicine, University of Cambridge, Cambridge, UK.
⁶ Cell Surface Signalling Laboratory, Wellcome Sanger Institute, Hinxton, UK.
⁷ Department of Biology, Hull York Medical School, and York Biomedical Research Institute, University of York, York, UK.
⁸ Division of Molecular Microbiology, School of Life Sciences, University of Dundee, Dundee, UK.
⁹ Departments of Pediatrics and Medicine, Center for Translational Research in Infection and Inflammation, Tulane University School of Medicine, New Orleans, Louisiana.
¹⁰ Ragon Institute of MGH, MIT and Harvard, Harvard Medical School, Cambridge, Massachusetts.
¹¹ Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
¹² Moderna Inc., Cambridge, Massachusetts.
¹³ Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford, UK.
¹⁴ The Tisch Cancer Institute and Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York.
¹⁵ Africa Health Research Institute, Durban, South Africa.
¹⁶ Department of Bioengineering, McGill University, Montreal, Quebec, Canada.
¹⁷ Measles and Respiratory Viruses Laboratory, WHO/NIC, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, Brazil.
¹⁸ Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland.
¹⁹ Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, Washington.
²⁰ Department of Medicine, University of Washington School of Medicine, Seattle, Washington.
²¹ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
²² Coalition for Epidemic Preparedness Innovations, Oslo, Norway.
²³ Harvard Medical School, Boston, Massachusetts.
²⁴ Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, California.
²⁵ Department of Infectious Disease, Imperial College London, London, UK.
²⁶ Division of Immunology, Department of Pathology, South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
²⁷ Malawi Liverpool Wellcome Research Programme, Blantyre, Malawi.
²⁸ Infection and Immunity, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
²⁹ Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia.
³⁰ Department of General Medicine, The Royal Children's Hospital, Melbourne, Victoria, Australia.
³¹ Microbiology Biocenter, University of Würzburg, Würzburg, Germany.
³² Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford Immunology Program, Stanford University School of Medicine, Stanford, California.
³³ Chan Zuckerberg Biohub, San Francisco, California.
³⁴ Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.
³⁵ National Children's Research Centre, Crumlin and School of Medicine, Trinity College Dublin, Dublin, Ireland.
³⁶ Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia.
³⁷ Immunology Program, Benaroya Research Institute at Virginia Mason, Seattle, Washington.
³⁸ Bill & Melinda Gates Foundation, Seattle, Washington.
³⁹ South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand, Johannesburg, South Africa.

PMID: 35029310
DOI: 10.1111/nyas.14739

Abstract

The rapid development of COVID-19 vaccines was the result of decades of research to establish flexible vaccine platforms and understand pathogens with pandemic potential, as well as several novel changes to the vaccine discovery and development processes that partnered industry and governments. And while vaccines offer the potential to drastically improve global health, low-and-middle-income countries around the world often experience reduced access to vaccines and reduced vaccine efficacy. Addressing these issues will require novel vaccine approaches and platforms, deeper insight how vaccines mediate protection, and innovative trial designs and models. On June 28-30, 2021, experts in vaccine research, development, manufacturing, and deployment met virtually for the Keystone eSymposium "Innovative Vaccine Approaches" to discuss advances in vaccine research and development.

Keywords: COVID-19; correlates of protection; human challenge studies; influenza; pneumococcal disease; streptococcus; vaccine equity; vaccines.

PubMed Disclaimer

References

1. Rappuoli, R. & P.R. Dormitzer. 2012. Influenza: options to improve pandemic preparation. Science 336: 1531-1533.
1. Rappuoli, R. & A. Aderem. 2011. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 473: 463-469.
1. Dormitzer, P.R., P. Suphaphiphat, D.G. Gibson, et al. 2013. Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci. Transl. Med. 5: 185ra68.
1. Hekele, A., S. Bertholet, J. Archer, et al. 2013. Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice. Emerg. Microbes Infect. 2: e52.
1. Paden, C.R., Y. Tao, K. Queen, et al. 2020. Rapid, sensitive, full-genome sequencing of severe acute respiratory syndrome coronavirus 2. Emerg. Infect. Dis. 26: 2401-2405.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Innovative vaccine approaches-a Keystone Symposia report

Affiliations

Innovative vaccine approaches-a Keystone Symposia report

Authors

Affiliations

Abstract

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous